Pharmaceutical patents: Incentives for research and development or marketing?

Southern Economic Journal

Volumn 76, Issue 2, 2009, Pages 351-374

  Brekke, Kurt R ^a   Straume, Odd Rune ^b,c  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Jel classification: i11; L13; O31

Indexed keywords

EID: 70449449850     PISSN: 00384038     EISSN: None     Source Type: Journal    
DOI: 10.4284/sej.2009.76.2.351     Document Type: Article

References (35)

1. Beath, John, Yannis Katsoulacos, and David Ulph. 1989. Strategic R&D policy. Economic Journal 99:74-83.
2. Berndt, Ernst R., Linda Bui, David R. Reiley, and Glen L. Urban. 1995. Information, marketing, and pricing in the US antiulcer drug market. American Economic Review 85:100-5.
3. Brekke, Kurt R., and Michael Kuhn. 2006. Direct to consumer advertising in pharmaceutical markets. Journal of Health Economics 25:102-30.
4. Brekke, Kurt R., Ingrid Königbauer, and Odd Rune Straume. 2007. Reference pricing of Pharmaceuticals. Journal of Health Economics 26:613-42.
5. Bulow, Jeremy, John D. Geanakoplos, and Paul D. Klemperer. 1985. Multimarket oligopoly: Strategic substitutes and complements. Journal of Political Economy 93:488-511.
6. Butters, Gerard R. 1977. Equilibrium distributions of sale and advertising prices. Review of Economic Studies 44:465-91.
7. Cabrales, Antonio. 2003. Pharmaceutical generics, vertical product differentiation, and public policy. Unpublished paper, Universitat Pompeu Fabra.
8. Caves, Richard E., Mark A. Hurwitz, and Michael D. Whinston. 1991. Patent expiration, entry, and competition in the U. S. pharmaceutical industry. Brookings Papers on Economic Activity, Microeconomics: 1-66.
9. Denicolo, Vincenzo. 1996. Patent races and optimal patent breadth and length. Journal of Industrial Economics 44:249-65.
10. Dixit, Avinash. 1980. The role of investment in entry deterrence. Economic Journal 90:95-106.
11. Ellison, Glenn, and Sara F. Ellison. 2007. Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. NBER Working Paper No. 13069.
12. Fudenberg, Drew, and Jean Tirole. 1984. The fat-cat effect, the puppy-dog ploy, and the lean and hungry look. American Economic Review 74:361-6.
13. Gilbert, Richard J., and David M. Newbery. 1982. Pre-emptive patenting and the persistence of monopoly. American Economic Review 72:514-26.
14. Grabowski, Henry G., and John M. Vernon. 1992. Brand loyalty, entry, and price competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35:331-50.
15. Grossman, Gene M., and Carl Shapiro. 1984. Informative advertising with differentiated products. Review of Economic Studies 51:63-81.
16. Hurwitz, Mark A., and Richard E. Caves. 1988. Persuasion or information? Promotion and the shares of brand name and generic Pharmaceuticals. Journal of Law and Economics 31:299-320.
17. Ishigaki, Hiroaki. 2000. Informative advertising and entry deterrence: A Bertrand model. Economic Letters 67:337-43.
18. Jaffe, Adam B. 2000. The U. S. patent system in transition: Policy innovation and the innovation process. Research Policy 29:531-57.
19. Kanavos, Panagiotis. 2001. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Commission of the European Communities, DG Enterprise, November.
20. Königbauer, Ingrid. 2007. Advertising and generic market entry. Journal of Health Economics 26:286-305.
21. Langinier, Corinne. 2004. Are patents strategic barriers to entry? Journal of Economics & Business 56:349-61.
22. Lu, Z. John, and William S. Comanor. 1998. Strategic pricing of new Pharmaceuticals. Review of Economics and Statistics 80:108-18.
23. Matraves, Catherine. 1999. Market structure, R&D and advertising in the pharmaceutical industry. Journal of Industrial Economics 47:169-94.
24. Needham, Douglas. 1976. Entry barriers and non-price aspects of firms' behavior. Journal of Industrial Economics 25:29-43.
25. Newhouse, Joseph P. 1993. Free for All? Lessons from the RAND Health Experiment. Cambridge, MA: Harvard University Press.
26. Reinganum, Jennifer F. 1983. Uncertain innovation and the persistence of monopoly. American Economic Review 73:741-78.
27. Rizzo, John A. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics 42:89-116.
28. Sakakibara, Mariko, and Lee Branstetter. 2001. Do stronger patents induce more innovation? Evidence from the 1988 Japanese patent law reforms. RAND Journal of Economics 32:77-100.
29. Schmalensee, Richard. 1983. Advertising and entry deterrence: An exploratory model. Journal of Political Economy 91:636-53.
30. Scherer, Frederic M., and David Ross. 1990. Industrial Market Structure and Economic Performance. Boston: Houghton Mifflin Company.
31. Scherer, Frederic M. 2000. The pharmaceutical industry. In Handbook of Health Economics, edited by Anthony J. Culyer and Joseph P. Newhouse. Amsterdam, North Holland: Elsevier, pp. 1297-1336.
32. Schweitzer, Stuart O. 1997. Pharmaceutical economics and policy. NY: Oxford University Press.
33. Scott Morton, Fiona M. 2000. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 18:1085-1104.
34. Waterson, Michael. 1990. The economics of product patents. American Economic Review 80:860-9.
35. Zweifel, Peter, and Friedriech Breyer. 1997. Health Economics. New York: Oxford University Press.